Serum microRNAs as Potential Biomarkers of Juvenile Idiopathic Arthritis
Serum microRNAs as Potential Biomarkers of Juvenile Idiopathic Arthritis
复制标题
DOI：
10.1007/s10067-015-2922-1
复制
发表时间：
2015-10-01
影响因子：
3.4
通讯作者：
Ito, Yoshinori
中科院分区：
文献类型：
--
作者：
Kamiya, Yasuko;Kawada, Jun-ichi;Ito, Yoshinori
微小RNA（microRNAs，miRNAs）是一类调控靶向mRNA表达的非编码RNA，在自身免疫性疾病的发病机制中起重要作用。miRNAs可能有潜力作为疾病的生物标志物。我们评估了选定的miRNAs的血清水平及其与幼年特发性关节炎（JIA）疾病活动的关系。收集JIA患者（8例全身性发作，16例多发性关节炎）和健康对照者的血清和外周血白细胞。定量miR-16、miR-132、miR-146 a、miR-155和miR-223的水平。全身性发作JIA患者血清中miR-223水平显著高于对照组。JIA患者和对照组外周血白细胞的MiRNA没有表现出任何差异。在全身性JIA和多发性关节炎患者中，miR-223和miR-16水平分别与红细胞沉降率和基质金属蛋白酶-3相关。miR-146 a和miR-223在多发性关节炎中显示与基质金属蛋白酶-3相关。JIA患者的miRNAs表达发生改变。血清miR-223水平可能是一种潜在的疾病生物标志物。对miRNAs的研究有助于理解JIA的发病机制，并有助于识别其他疾病生物标志物。
MicroRNAs (miRNAs) are non-coding RNAs that regulate gene expression of targeted mRNAs, which are important in the pathogenesis of autoimmune diseases. MiRNAs may have the potential to serve as biomarkers of disease. We evaluated serum levels of selected miRNAs and their associations with disease activity in juvenile idiopathic arthritis (JIA). Sera and peripheral blood leukocytes were collected from patients with JIA (8 systemic onset, 16 polyarthritis) and healthy controls. Levels of miR-16, miR-132, miR-146a, miR-155, and miR-223 were quantified. Levels of miR-223 in sera were significantly higher in patients in the active phase of systemic onset JIA than in controls. MiRNAs of peripheral blood leukocytes did not exhibit any difference between patients with JIA and controls. In both systemic onset JIA and polyarthritis patients, levels of miR-223 and miR-16 correlated with erythrocyte sedimentation rate and matrix metalloproteinase-3, respectively. MiR-146a and miR-223 in polyarthritis showed correlations with matrix metalloproteinase-3. Expressions of miRNAs were altered in patients with JIA. Serum levels of miR-223 may be a potential disease biomarker. Investigation of miRNAs could be helpful in understanding the pathogenesis of JIA and could aid in the identification of additional disease biomarkers.